Abstract

N-Heterocyclic carbene (NHC) gold(I) complexes offer great prospects in medicinal chemistry as antiproliferative, anticancer, and antibacterial agents. However, further development requires a thorough understanding of their reaction behavior in aqueous media. Herein, we report the conversion of the bromido[3-ethyl-4-(4-methoxyphenyl)-5-(2-methoxypyridin-5-yl)-1-propylimidazol-2-ylidene]gold(I) ((NHC)AuIBr, 1) complex in acetonitrile/water mixtures to the bis[3-ethyl-4-(4-methoxyphenyl)-5-(2-methoxypyridin-5-yl)-1-propylimidazol-2-ylidene]gold(I) ([(NHC)2AuI]+, 7), which is subsequently oxidized to the dibromidobis[3-ethyl-4-(4-methoxyphenyl)-5-(2-methoxypyridin-5-yl)-1-propylimidazol-2-ylidene]gold(III) ([(NHC)2AuIIIBr2]+, 9). By combining experimental data from HPLC, NMR, and (LC-)/HR-MS with computational results from DFT calculations, we outline a detailed ligand scrambling reaction mechanism. The key step is the formation of the stacked ((NHC)AuIBr)2 dimer (2) that rearranges to the T-shaped intermediate Br(NHC)2AuI–AuIBr (3). The dissociation of Br– from 3 and recombination lead to (NHC)2AuI–AuIBr2 (5) followed by the separation into [(NHC)2AuI]+ (7) and [AuIBr2]− (8). [AuIBr2]− is not stable in an aqueous environment and degrades in an internal redox reaction to Au0 and Br2. The latter in turn oxidizes 7 to the gold(III) species 9. The reported ligand rearrangement of the (NHC)AuIBr complex differs from that found for related silver(I) analogous. A detailed understanding of this scrambling mechanism is of utmost importance for the interpretation of their biological activity and will help to further optimize them for biomedical and other applications.

Highlights

  • Discovering gold(I) and gold(III) complexes as catalysts,[1] luminescence agents,[2−4] and more recently as anticancer and antibacterial agents in medicinal chemistry[5−9] pushed forward the research in gold chemistry

  • Complexes bearing phosphine and/or thiol ligands with the famous representative auranofin,[10,11] cyclometalated gold(III) complexes with C, N donor ligands, and N-heterocyclic carbene (NHC) gold(I) complexes arose in the past as auspicious compounds against abnormal cell growth.[7,12−14] In particular, (NHC)AuIX and related complexes came into the focus of medicinal chemists and were examined for their suitability as chemotherapeutic agents.[6,9,15−19] The straightforward synthesis of the NHC ligands, the possibility of fine-tuning the physicochemical properties, and the reactivity of the resulting (NHC) gold(I) complexes make the latter to attractive lead structures for the development of novel metal-based drugs

  • The stability of 1 in pure ACN (1 mM) at RT was studied by HPLC at 0, 24, 48, and 72 h

Read more

Summary

Introduction

Discovering gold(I) and gold(III) complexes as catalysts,[1] luminescence agents,[2−4] and more recently as anticancer and antibacterial agents in medicinal chemistry[5−9] pushed forward the research in gold chemistry. Complexes bearing phosphine and/or thiol ligands with the famous representative auranofin,[10,11] cyclometalated gold(III) complexes with C, N donor ligands, and N-heterocyclic carbene (NHC) gold(I) complexes arose in the past as auspicious compounds against abnormal cell growth.[7,12−14] In particular, (NHC)AuIX and related complexes came into the focus of medicinal chemists and were examined for their suitability as chemotherapeutic agents.[6,9,15−19] The straightforward synthesis of the NHC ligands, the possibility of fine-tuning the physicochemical properties, and the reactivity of the resulting (NHC) gold(I) complexes make the latter to attractive lead structures for the development of novel metal-based drugs. Ligand exchange reactions were investigated for various (NHC)AuIX complexes[17,27] indicating a strong trans effect of the NHC and a preferred exchange of X as leaving group. It is well accepted that the observed biological response depends on the ligand exchange rate.[28−30] the suitability of NHCs as leaving groups was investigated, too. Dos Santos et al, for instance, studied the Received: August 3, 2020 Published: October 2, 2020

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call